Literature DB >> 17828783

Short health scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn's disease.

Henrik Stjernman1, Christer Grännö, Gunnar Järnerot, Leif Ockander, Curt Tysk, Björn Blomberg, Magnus Ström, Henrik Hjortswang.   

Abstract

BACKGROUND: Health-related quality of life (HRQoL) is an essential part of inflammatory bowel disease (IBD) assessment. The Short Health Scale (SHS), an HRQoL questionnaire in which the patients rate the disease impact on 4 important aspects of subjective health (symptoms, function, worry, and general well-being) was demonstrated in a previous study to be valid, reliable, and responsive in patients with ulcerative colitis. The present study evaluates the SHS in patients with Crohn's disease (CD).
METHODS: In all, 367 CD patients completed the SHS and 4 other HRQoL questionnaires (IBDQ, SF-36, RFIPC, and PGWB) at their regular outpatient visits. Then 330 patients completed the questionnaires at a second visit 6 months later. In addition, reliability data were obtained from repeat measurements 4 weeks after the first visit in 40 patients stable in remission.
RESULTS: Patients in remission scored better on all 4 questions than those with active disease (P < 0.001). All 4 questions were strongly correlated with the corresponding dimensions of the other HRQoL questionnaires (r(s) = 0.74-0.83). Reliability was confirmed with strong test-retest correlations (r(s) = 0.69-0.82) and intraclass correlation coefficients (0.66-0.77). Patients who changed from remission to active disease or vice versa showed a significant change in all 4 SHS scores (P < 0.005).
CONCLUSIONS: SHS is a valid, reliable and responsive HRQoL instrument also in patients with CD. It is easily completed by the patient and requires no further calculation by the investigator. SHS gives a comprehensive overview of the main aspects of the patient's subjective health perception and is a useful tool in both clinical practice and clinical studies.

Entities:  

Mesh:

Year:  2008        PMID: 17828783     DOI: 10.1002/ibd.20255

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  20 in total

1.  Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS).

Authors:  Lars-Petter Jelsness-Jørgensen; Tomm Bernklev; Bjørn Moum
Journal:  Qual Life Res       Date:  2011-12-07       Impact factor: 4.147

2.  Framework for assessing quality of care for inflammatory bowel disease in Sweden.

Authors:  Martin Rejler; Jörgen Tholstrup; Mattias Elg; Anna Spångéus; Boel Andersson Gäre
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

3.  Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.

Authors:  Annelie Lindberg; Michael Eberhardson; Mats Karlsson; Per Karlén
Journal:  BMC Gastroenterol       Date:  2010-07-06       Impact factor: 3.067

4.  A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match?

Authors:  Allison R Wilcox; Maria Concepcion C Dragnev; Christopher J Darcey; Corey A Siegel
Journal:  Inflamm Bowel Dis       Date:  2010-04       Impact factor: 5.325

5.  Attachment and quality of life in patients with inflammatory bowel disease.

Authors:  Alessandro Agostini; Marco Moretti; Carlo Calabrese; Fernando Rizzello; Paolo Gionchetti; Mauro Ercolani; Massimo Campieri
Journal:  Int J Colorectal Dis       Date:  2014-07-19       Impact factor: 2.571

Review 6.  Microscopic colitis.

Authors:  Kristin E Burke; Mauro D'Amato; Siew C Ng; Darrell S Pardi; Jonas F Ludvigsson; Hamed Khalili
Journal:  Nat Rev Dis Primers       Date:  2021-06-10       Impact factor: 52.329

7.  Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.

Authors:  Andreas Münch; Johan Bohr; Stephan Miehlke; Cecilia Benoni; Martin Olesen; Åke Öst; Lars Strandberg; Per M Hellström; Erik Hertervig; Peter Armerding; Jiri Stehlik; Greger Lindberg; Jan Björk; Annika Lapidus; Robert Löfberg; Ole Bonderup; Sören Avnström; Martin Rössle; Karin Dilger; Ralph Mueller; Roland Greinwald; Curt Tysk; Magnus Ström
Journal:  Gut       Date:  2014-11-25       Impact factor: 23.059

8.  Effects of Arabinoxylan and Resistant Starch on Intestinal Microbiota and Short-Chain Fatty Acids in Subjects with Metabolic Syndrome: A Randomised Crossover Study.

Authors:  Stine Hald; Anne Grethe Schioldan; Mary E Moore; Anders Dige; Helle Nygaard Lærke; Jørgen Agnholt; Knud Erik Bach Knudsen; Kjeld Hermansen; Maria L Marco; Søren Gregersen; Jens F Dahlerup
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

9.  Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.

Authors:  Nienke Lesuis; Ragnar Befrits; Filippa Nyberg; Ronald F van Vollenhoven
Journal:  BMC Med       Date:  2012-08-01       Impact factor: 8.775

Review 10.  The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease.

Authors:  Lone Larsen; Michael Dam Jensen; Michael Due Larsen; Rasmus Gaardskær Nielsen; Niels Thorsgaard; Ida Vind; Signe Wildt; Jens Kjeldsen
Journal:  Clin Epidemiol       Date:  2016-10-25       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.